Navigation Links
Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
Date:4/18/2013

LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity.  One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. 

Because Replikins is leveraging proprietary software techniques to isolate targeted regions in the virus, combined with recent advances in manufacturing synthetic peptides, the company and its partners are able to provide rapid turnaround of vaccine candidates based on early data emerging from disease outbreaks.  This approach stands in marked contrast to projections by other companies of delays of seven months or longer before vaccines can be made available, and makes it possible to consider effective public health responses to disease outbreaks while they are still at an early stage.

Replikins will provide details of the technology and is seeking partnerships at the BIO International Convention April 22nd-25th at its booth #3456, McCormick Place, Chicago.

The technique used to create Replikins' new synthetic vaccine candidates is similar to those the company used in manufacturing a successful Replikins H5N1 "bird flu" vaccine in chickens in a paper published in 2009.  That vaccine was produced in 7 days, shipped freeze-dried, and administered via the respiratory tract.  Significantly, in addition to stopping the virus in the chickens, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.

Contact: Dr. Samuel Bogoch , 646-320-5910, Email

References:

1.  Nature Precedings.  Bogoch et al, doi:10.1038/npre.2012.6952.1

(see also seven additional  Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.

2.  www.replikins.com

3. Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)

4. Jackwood et al. Avian Diseases 53(4): 613‐617, 2009

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
2. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Generex Announces Details of Investor Conference Call
5. White Paper Details Five Things to Consider Before Buying Spiral Bevel Gear Drives
6. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
7. New Report Details NCPA Efforts to Drive Greater Medication Adherence
8. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
9. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):